SAVA

About SAVA

Cassava Sciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in the detection and treatment of neurodegenerative diseases, such as Alzheimer’s disease. The Company develops pharmaceutical product candidates that offer improvements to patients and healthcare professionals. The Company has two biopharmaceutical assets under development, including its lead therapeutic product candidate, called simufilam, is an oral treatment for Alzheimer’s disease dementia, which is under Phase III clinical studies; and its lead investigational diagnostic product candidate, called SavaDx, is a way to detect the presence of Alzheimer’s disease from a small sample of blood. Simufilam is a proprietary small molecule (oral) drug, which targets an altered form of a protein called filamin A (FLNA) in the Alzheimer’s brain. SavaDx is designed as an antibody-based detection system for altered filamin A (FLNA).